Healthcare Industry News: IPLEX
News Release - June 1, 2006
Cynosure Receives Approval to Market Cynergy(R) Workstation with MultiPlex(TM) Technology Laser System in CanadaWESTFORD, Mass., June 1 (HSMN NewsFeed) -- Cynosure, Inc. (Nasdaq: CYNO ), a leading developer and manufacturer of lasers and pulsed light sources, today announced it has received Class III medical device license approval from Health Canada to market and sell its flagship Cynergy® workstation with MultiPlex(TM) technology in Canada.
"Canada represents an important market for our products," said Michael R. Davin, CEO of Cynosure, Inc. "With this Health Canada approval, physicians throughout the United States and Canada can now use the Cynergy workstation with MultIPLEX technology for numerous conditions that were previously deemed untreatable or difficult to treat, doing so with a greater control of outcome, patient comfort and safety.
"We believe the Cynergy workstation with MultIPLEX technology is the premier laser technology for vascular applications, and an important dermatological tool that addresses many cosmetic applications from veins, birthmarks and pigmented lesions, to high volume services such as hair removal and skin rejuvenation," Davin said.
The Cynergy workstation with MultIPLEX technology is the first system available that can sequentially emit with rapid succession, two wavelengths from the same fiber optic -- a pulsed dye laser and an Nd:YAG laser. The adjustable time delay between pulses increases the safety and effectiveness of laser treatment. Cynosure plans to market the Cynergy workstation with MultIPLEX technology in Canada through its direct sales force.
"We believe international markets can be key contributors in driving the adoption of our Cynergy workstation with MultIPLEX technology," Davin said. "Initial demand in the United States has been strong, and we are looking to continue this success in Canada."
In a clinical study presented at the American Society for Lasers in Medicine and Surgery in April 2006, by Dr. Emil Tanghetti, M.D., clinical professor of cosmetic dermatology at the University of California, Davis, it was shown that treatments utilizing the Cynergy workstation with MultIPLEX technology have an improved effectiveness in addressing facial and leg telangiectasia when compared to treatments using a pulsed dye laser or an Nd:YAG laser individually. This study demonstrated that in 75 percent of the patients treated with this system, 70-80% clearance was achieved for these types of lesions with a single treatment.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.
For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosurelaser.com.
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the markets in which Cynosure's products are sold and the use of and demand for the Cynergy workstation with MultIPLEX technology, and other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important risk factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in documents filed with the Securities and Exchange Commission, including Cynosure's Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.